HOMECONTACTSITE MAPIMPRINT
CeNS Center for NanoScience LMU Ludwig-Maximilians-Universität München
CeNS HomepageLMU Homepage
Home  >  News  >  Press review

Wednesday, 09 November, 2022

A new nanoparticle to act at the heart of cells

A team from UNIGE and LMU developed a transport nanoparticle to make an anti-inflammatory drug much more effective and less toxic.

How can a drug be delivered exactly where it is needed, while limiting the risk of side effects? The use of nanoparticles to encapsulate a drug to protect it until it reaches its point of action is being increasingly studied. However, this requires identifying the right nanoparticle for each drug according to a series of precise parameters. A team from the University of Geneva (UNIGE) and LMU has succeeded in developing a fully biodegradable nanoparticle capable of delivering a new anti-inflammatory drug directly into macrophages - the cells where uncontrolled inflammatory reactions are triggered - ensuring its effectiveness. In addition, the scientists used an in vitro screening methodology, thus limiting the need for animal testing. These results, recently published in the Journal of Controlled Release, open the way to an extremely powerful and targeted anti-inflammatory treatment.

For the press release from the University of Geneva, click here: Opens external link in new windowLink